Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
diacylglycerol/obezitate
Linkul este salvat în clipboard
Pagină 1 din 38 rezultate
Modulation of diacylglycerol acyltransferase 1 expression
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
Triglycerides are one of the major energy storage molecules in eukaryotes. The absorption of triglycerides (also called triacylglycerols) from food is a very efficient process that occurs by a series of steps wherein the dietary triacylglycerols are hydrolyzed in the
Modulation of diacylglycerol acyltransferase 1 expression
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
Triglycerides are one of the major energy storage molecules in eukaryotes. The absorption of triglycerides (also called triacylglycerols) from food is a very efficient process that occurs by a series of steps wherein the dietary triacylglycerols are hydrolyzed in the
Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION
The present invention relates to certain heterocyclic compounds useful as diacylglycerol acyltransferase ("DGAT") inhibitors, especially diacylglycerol acyltransferase 1 ("DGAT1") inhibitors, pharmaceutical compositions containing the compounds, and methods of treatment using
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
Obesity, the most prevalent of body weight disorders, is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Obesity, defined as an excess of body fat relative to lean
Inhibitors of diacylglycerol acyltransferase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION
The invention involves inhibitors of diacylglycerol acyltransferase. The inhibitors are useful for the treatment of diseases such as obesity, type II diabetes mellitus, dyslipidemia and metabolic syndrome.
All documents cited or relied upon below are expressly incorporated
Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the
Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the
Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI >30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the
Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the
Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
INTRODUCTION
1. Field of the Invention
The invention relates generally to methods of treating conditions associated with abnormal carbohydrate metabolism, such as obesity and diabetes. Specifically, the invention relates to methods of modulating insulin and/or leptin sensitivity in a host.
2.
Compounds as diacylglycerol acyltransferase inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF INVENTION
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases
Compounds as diacylglycerol acyltransferase inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF INVENTION
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases
Compounds as diacylglycerol acyltransferase inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF INVENTION
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases
Cea mai completă bază de date cu plante medicinale susținută de știință
- Funcționează în 55 de limbi
- Cure pe bază de plante susținute de știință
- Recunoașterea ierburilor după imagine
- Harta GPS interactivă - etichetați ierburile în locație (în curând)
- Citiți publicațiile științifice legate de căutarea dvs.
- Căutați plante medicinale după efectele lor
- Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele
Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate
